Advancements in the synergy of isothermal amplification and CRISPR-cas technologies for pathogen detection.

In the realm of pathogen detection, isothermal amplification technology has emerged as a swift, precise, and sensitive alternative to conventional PCR. This paper explores the fundamental principles of recombinase polymerase amplification (RPA) and recombinase-aid amplification (RAA) and reviews the current status of integrating the CRISPR-Cas system with RPA/RAA techniques. Furthermore, this paper explores the confluence of isothermal amplification and CRISPR-Cas technology, providing a comprehensive review and enhancements of existing combined methodologies such as SHERLOCK and DETECTR. We investigate the practical applications of RPA/RAA in conjunction with CRISPR-Cas for pathogen detection, highlighting how this integrated approach significantly advances both research and clinical implementation in the field. This paper aims to provide readers with a concise understanding of the fusion of RPA/RAA and CRISPR-Cas technology, offering insights into their clinical utility, ongoing enhancements, and the promising prospects of this integrated approach in pathogen detection.

Upregulation of B3GNT3 is associated with immune infiltration and activation of NF-κB pathway in gynecologic cancers.

Beta-1,3-N-acetylglucosaminyltransferase-3 (B3GNT3) is a carcinogenic factor in many cancers. However, the biological functions of B3GNT3 in gynecologic cancers especially in cervical, ovarian, and endometrial cancers are mostly limited. B3GNT3 levels in pan-cancer and gynecologic cancers were predicted by GSCA, GEPIA, and the Human Protein Atlas databases. The overall survival was predicted by Kaplan-Meier Plotter. ROC curve was generated according to the TCGA database. The immune cell infiltration was analyzed by ImmuCellAI algorithm using GSCA database. The related genes and pathways were analyzed via LinkedOmics portal, GO, KEGG pathway enrichment analysis, and GEPIA database. B3GNT3, p-p65/p65, and nuclear p65 levels were detected by western blotting. B3GNT3 was differentially expressed in pan-cancers. B3GNT3 expression was increased in cervical, ovarian, and endometrial cancers. High expression of B3GNT3 was associated with lower overall survival, and was used for diagnosis of these gynecologic cancers. B3GNT3 was related to different immune cell infiltration. B3GNT3 was associated with NF-κB signaling activation by regulating multiple related biomarkers. Silencing of B3GNT3 repressed activation of the NF-κB signaling in gynecologic cancers. In conclusion, upregulated B3GNT3 is related to diagnosis, poor prognosis, immune infiltration, and activation of the NF-κB signaling in gynecologic cancers.